Search
for
Sort by
Research 61–90 of 1000+
- Safety of treatment options for spondyloarthritis: a narrative review
- Safety of Platelet‐Rich Plasma Subepithelial Infusion for Vocal Fold Scar, Sulcus, and Atrophy
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- AB0597 Comparative analysis of safety data of four treatment regimens in early rheumatoid arthritis patients
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Safety concerns when using novel medications to treat alopecia
- Efficacy and safety of oral minoxidil in female androgenetic alopecia
- Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
- Human Dermal Safety Studies with Eflornithine HCl 13.9% Cream (Vaniqa™), a Novel Treatment for Excessive Facial Hair
- Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
- Pharmacokinetics and Safety of 1 mg Oral Minoxidil Tablets in Healthy Female Volunteers: A Phase I Randomized Crossover Clinical Trial
- Amelioration of psoriasis-like skin lesions by human amniotic mesenchymal stem cells: insights from multiomics profiling in mice
- Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real‐World Pharmacovigilance Study
- (369) Physician Insights into the Safety of Flibanserin for the Treatment of Sexual Dysfunction in Men
- Safety and Effectiveness of a Novel Hyaluronic Acid Gel for Lip Augmentation
- Safety and efficacy of a topical treatment (SM04554) for androgenetic alopecia (AGA): Results from a phase 1 Trial
- Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis
- Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
- Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program
- Efficacy and Safety of Fractional Laser Therapy for Androgenetic Alopecia: A Systematic Review and Meta‐Analysis
- Topical Application of Bio-Pulsed Avian MSC-Derived Extracellular Vesicles Enhances Hair Regrowth and Skin Rejuvenation: Evidence from Clinical Evaluation and miRNA Profiling
- Efficacy and safety of spironolactone versus bicalutamide in female pattern hair loss: A retrospective comparative study
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- A10.09 Safety data of four treatment regimens in early rheumatoid arthritis patients
- Efficacy and Safety of SER120 Nasal Spray in Patients with Nocturia: Pooled Analysis of 2 Randomized, Double-Blind, Placebo Controlled, Phase 3 Trials
- Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Efficacy and safety of non‐cross‐linked hyaluronic acid compound in the treatment of keratosis pilaris: A split‐body randomized clinical trial